Cefiderocol-Based Combination Therapy for “Difficult-to-Treat” Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives

Cefiderocol-Based Combination Therapy for “Difficult-to-Treat” Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives

Cefiderocol is a new cephalosporin displaying against extensively resistant (XDR) Gram-negative bacteria. We report our experience with cefiderocol-based combination therapies as “rescue” treatments in immunocompromised or critically ill patients or in patients with post-surgical infections who had...

Full description

Bibliographic Details
Main Authors:	Davide Fiore Bavaro, Alessandra Belati, Lucia Diella, Monica Stufano, Federica Romanelli, Luca Scalone, Stefania Stolfa, Luigi Ronga, Leonarda Maurmo, Maria Dell’Aera, Adriana Mosca, Lidia Dalfino, Salvatore Grasso, Annalisa Saracino
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Series:	Antibiotics
Subjects:	cefiderocol multidrug resistant gram-negative bacteria novel antimicrobial strategies <i>Pseudomonas aeruginosa</i> <i>Acinetobacter baumannii</i> <i>Klebsiella pneumoniae</i>
Online Access:	https://www.mdpi.com/2079-6382/10/6/652

Similar Items

Cefiderocol Versus Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream Infections: A Retrospective, Propensity-Score Adjusted, Monocentric Cohort Study
by: Davide Fiore Bavaro, et al.
Published: (2023-09-01)

Effectiveness of First-Line Therapy with Old and Novel Antibiotics in Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant <i>Acinetobacter baumannii</i>: A Real Life, Prospective, Observational, Single-Center Study
by: Lidia Dalfino, et al.
Published: (2023-06-01)

Human Serum Proteins and Susceptibility of <i>Acinetobacter baumannii</i> to Cefiderocol: Role of Iron Transport
by: Casin Le, et al.
Published: (2022-03-01)

Cefiderocol Treatment for Severe Infections due to Difficult-to-Treat-Resistant Non-Fermentative Gram-Negative Bacilli in ICU Patients: A Case Series and Narrative Literature Review
by: Paul-Henri Wicky, et al.
Published: (2023-06-01)

Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of <i>Acinetobacter baumannii</i> Clinical Isolates
by: Clara Ballesté-Delpierre, et al.
Published: (2022-01-01)

In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against <i>Acinetobacter baumannii</i> Strains Recovered from Clinical Samples
by: Davide Carcione, et al.
Published: (2021-10-01)

Cefiderocol for Severe Carbapenem-Resistant <i>A. baumannii</i> Pneumonia: Towards the Comprehension of Its Place in Therapy
by: Emanuele Rando, et al.
Published: (2021-12-01)

Performance of the Disc Diffusion Method, MTS Gradient Tests and Two Commercially Available Microdilution Tests for the Determination of Cefiderocol Susceptibility in <i>Acinetobacter</i> spp.
by: Katy Jeannot, et al.
Published: (2023-07-01)

Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations
by: Andrea Marino, et al.
Published: (2022-12-01)

The Iron Content of Human Serum Albumin Modulates the Susceptibility of <i>Acinetobacter baumannii</i> to Cefiderocol
by: Jenny Escalante, et al.
Published: (2023-02-01)

Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic
by: Maria Mazzitelli, et al.
Published: (2023-04-01)

In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany
by: Beniam Ghebremedhin, et al.
Published: (2021-09-01)

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant <i>Acinetobacter baumannii</i>
by: Arta Karruli, et al.
Published: (2023-12-01)

Induced Heteroresistance in Carbapenem-Resistant <i>Acinetobacter baumannii</i> (CRAB) via Exposure to Human Pleural Fluid (HPF) and Its Impact on Cefiderocol Susceptibility
by: Vyanka Mezcord, et al.
Published: (2023-07-01)

In Vitro Activity of Cefiderocol against Clinical Gram-Negative Isolates Originating from Germany in 2016/17
by: Esther Wohlfarth, et al.
Published: (2023-05-01)

Comparison of Disk Diffusion, E-Test, and Broth Microdilution Methods for Testing In Vitro Activity of Cefiderocol in <i>Acinetobacter baumannii</i>
by: Natalia Kolesnik-Goldmann, et al.
Published: (2023-07-01)

Genomic characterization of an NDM-9-producing Acinetobacter baumannii clinical isolate and role of Glu152Lys substitution in the enhanced cefiderocol hydrolysis of NDM-9
by: Susie Gaillot, et al.
Published: (2023-08-01)

Acinetobacter baumannii and Cefiderocol, between Cidality and Adaptability
by: Stefano Stracquadanio, et al.
Published: (2022-10-01)

Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?
by: Silvia Corcione, et al.
Published: (2022-09-01)

Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study
by: Alexandre Bleibtreu, et al.
Published: (2021-01-01)

Shifting Gears: The Future of Polymyxin Antibiotics
by: Justin R. Lenhard, et al.
Published: (2019-04-01)

Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections
by: Amer El Ghali, et al.
Published: (2024-02-01)

Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance
by: Matteo Bassetti, et al.
Published: (2020-09-01)

Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysis
by: Christopher Longshaw, et al.
Published: (2023-12-01)

Gastrointestinal Colonization of Carbapenem-Resistant <i>Acinetobacter baumannii</i>: What Is the Implication for Infection Control?
by: Shuk-Ching Wong, et al.
Published: (2022-09-01)

SUSCETIBILIDADE DE CEFIDEROCOL ENTRE PSEUDOMONAS AERUGINOSA E COMPLEXO ACINETOBACTER BAUMANNII (CAB) EM HOSPITAL TERCIÁRIO DE PORTO ALEGRE
by: Deise Reis Carvalho, et al.
Published: (2023-10-01)

Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii
by: Alessandra Oliva, et al.
Published: (2020-12-01)

Impact of a Pro-Active Infectious Disease Consultation on the Management of a Multidrug-Resistant Organisms Outbreak in a COVID-19 Hospital: A Three-Months Quasi-Experimental Study
by: Davide Fiore Bavaro, et al.
Published: (2023-04-01)

An <i>Acinetobacter</i> non-<i>baumannii</i> Population Study: Antimicrobial Resistance Genes (ARGs)
by: Adam Baraka, et al.
Published: (2020-12-01)

Isolation and Characterization of a Novel <i>Siphoviridae</i> Phage, vB_AbaS_TCUP2199, Infecting Multidrug-Resistant <i>Acinetobacter baumannii</i>
by: Meity Mardiana, et al.
Published: (2022-06-01)

Impact of SARS-CoV-2 Epidemic on Antimicrobial Resistance: A Literature Review
by: Francesco Vladimiro Segala, et al.
Published: (2021-10-01)

Whole-Genome Sequencing of ST2 <i>A. baumannii</i> Causing Bloodstream Infections in COVID-19 Patients
by: Sabrina Cherubini, et al.
Published: (2022-07-01)

Comparative Antimicrobial Activity of Hp404 Peptide and Its Analogs against <i>Acinetobacter baumannii</i>
by: Min Ji Hong, et al.
Published: (2021-05-01)

Extensive Drug Resistance of Strong Biofilm-Producing <i>Acinetobacter baumannii</i> Strains Isolated from Infections and Colonization Hospitalized Patients in Southern Poland
by: Tomasz Kasperski, et al.
Published: (2023-07-01)

Prevalence of Carbapenem Resistance Genes among <i>Acinetobacter baumannii</i> Isolated from a Teaching Hospital in Taiwan
by: Pai-Wei Su, et al.
Published: (2023-08-01)

<i>Acinetobacter baumannii</i> Resistance: A Real Challenge for Clinicians
by: Rosalino Vázquez-López, et al.
Published: (2020-04-01)

Current State of Antimicrobial Treatment of Lower Respiratory Tract Infections Due to Carbapenem-Resistant <i>Acinetobacter baumannii</i>
by: Marco Merli, et al.
Published: (2023-05-01)

Clinical Outcomes and Safety of Meropenem–Colistin versus Meropenem–Tigecycline in Patients with Carbapenem-Resistant <i>Acinetobacter baumannii</i> Pneumonia
by: Jae-Min Park, et al.
Published: (2021-07-01)

Antimicrobial and Antibiofilm Effects of Peptides from Venom of Social Wasp and Scorpion on Multidrug-Resistant <i>Acinetobacter baumannii</i>
by: Rogério Coutinho das Neves, et al.
Published: (2019-04-01)

Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients
by: Helen Giamarellou, et al.
Published: (2022-07-01)